The pending Boston Scientific acquisition overrides near-term earnings dynamics. Monitor regulatory approval milestones and any updates on the merger timeline, as deal completion is the primary catalyst.
Price Chart
Executive Summary
Penumbra reported Q3 2026 revenue of $410.1M, up 15.6% YoY and above the $400.1M consensus, with GAAP diluted EPS of $1.07 versus the $1.18 consensus estimate, a miss of 9.3%. The company did not provide financial guidance due to the pending acquisition by Boston Scientific, which is the dominant factor for the stock.
Key Financial Metrics
Key Facts
- Revenue of $410.1M, up 15.6% YoY, above consensus of $400.1M
- GAAP diluted EPS of $1.07, below consensus of $1.18
- Global thrombectomy revenue of $279.2M, up 18.1% YoY
- Global embolization and access revenue of $131.0M, up 10.8% YoY
- Gross profit margin of 68.3%, up 0.5% YoY
- Income from operations of $50.7M; net income of $42.3M
- No financial guidance provided due to pending acquisition by Boston Scientific
- Acquisition-related expenses of $7.1M in SG&A
Financial Impact
Revenue beat consensus by $10M (2.5%); EPS missed consensus by $0.11 (9.3%); net income of $42.3M vs $45.9M in Q3 2025
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Thrombectomy | $279.2M | +18.1% |
| Embolization and Access | $131.0M | +10.8% |
Risk Factors
- Pending acquisition may not close in expected timeframe or at all due to regulatory hurdles
- EPS miss of 9.3% versus consensus, though revenue beat partially offsets
- No guidance provided, limiting visibility into standalone performance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-prn-302922852 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Oct 29, 2026 3d ago | Press Release | $321.97 | awaiting T+60 | awaiting T+60 | $318.95 (−0.94%) |
Jul 30, 2026 13w ago | Press Release | $321.19 $325.22 | ▼ −1.25% | ▲ +1.20% | $318.95 (+0.70%) |
May 7, 2026 25w ago | 425 | $324.65 $323.02 | ▼ −0.50% | ▼ −4.34% | $318.95 (−1.76%) |
May 6, 2026 25w ago | 8-K | $324.65 $323.02 | ▲ +0.50% | ▲ +4.34% | $318.95 (+1.76%) |
Apr 29, 2026 26w ago | DEFA14A | $326.48 $319.49 | ▼ −2.14% | ▼ −5.25% | $318.95 (−2.31%) |
Apr 17, 2026 28w ago | 425 | $329.71 $316.73 | ▼ −3.94% | ▼ −10.71% | $318.95 (−3.26%) |
Apr 1, 2026 30w ago | DEFM14A | $330.36 $315.75 | ▼ −4.42% | ▼ −18.58% | $318.95 (−3.45%) |
Feb 25, 2026 35w ago | 8-K | $338.67 $327.38 | ▼ −3.33% | ▼ −10.28% | $318.95 (−5.82%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers